BRIEF-Syros announces FDA acceptance of IND to advance SY-1365
April 10 Syros Pharmaceuticals Inc
* Syros announces FDA acceptance of IND to advance SY-1365, its first-in-class selective CDK7 inhibitor, into phase 1 clinical trial in patients with advanced solid tumors
* Syros Pharmaceuticals Inc - company on track to initiate study in Q2 of 2017 Source text for Eikon: Further company coverage: